PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at mitigating Cannabis ...

Schrödinger faces financial losses amid investment in experimental drugs. Key 2025 trial results will reveal its future ...

Alphamab Oncology has dosed the first subject in the randomised Phase III JSKN003-306 trial of its anti-human epidermal ...

Received overwhelming shareholder support in favour of take-private transaction with AditxtAdvanced key pipeline programs, engaged regulatory ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Researchers identified three new all-oral drug regimens that include at least one of two new drugs for treatment of ...

If you enrolled in an optional Medicare Part D plan in 2024 or before, at some point you probably faced a coverage gap called the “donut hole,” a temporary limit on what your Part D plan will pay for ...

The federal government has long sought to prevent the horrors of drug addiction by interdicting the supply of dangerous ...

Researchers at the University of Toronto see a future where a single injection under the eyelid could replace months of daily ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...